Complete response of cerebral metastases of a mutated EGFR bronchopulmonary cancer treated with afatinib: clinical case and review of the literature.

H.Ouahbi; Lamiae Naouikh; Nissrine Acharfi; L.Moncelly; N.Mellas; C.Locher

Volume : IX, Issue : V, May - 2019

Complete response of cerebral metastases of a mutated EGFR bronchopulmonary cancer treated with afatinib: clinical case and review of the literature.

H. Ouahbi, Lamiae Naouikh, Nissrine Acharfi, L. Moncelly, N. Mellas, C. Locher

Abstract :

Afatinib is a second generation EGFR receptor tyrosine kinase inhibitor (ITK–EGFR). It has been shown to be effective in onchopulmonary cancers with EGFR receptor mutation. a complete tumor response in case of ain metastases is rarely described in the literature. We report the case of a patient with metastatic onchopulmonary adenocarcinoma at the cereal level with a double mutatuion of EGFR, having presented a complete and durable response to afatinib. we recall the data of the literature on this subject